IRVINE, Calif., June 22 /PRNewswire-FirstCall/ —
Cardiogenesis Corporation (OTCQB: CGCP) today announced that its
shares are now being quoted on the newly launched OTCQB™
market. Launched in April 2010, the
OTCQB is a new market tier for OTC-traded U.S. companies that are
registered and reporting with the Securities and Exchange
Commission (SEC). As a result of Cardiogenesis’ OTCQB designation,
investors can now view real-time stock quotes with market depth
(level 2). Listings may be found at http://www.otcmarkets.com.

“We are pleased to be listed on the OTCQB Market, a platform
which provides increased trading transparency and efficiency, for
our shareholders and potential investors,” said Paul McCormick, Executive Chairman. “We
believe that listing on this higher OTC tier will provide improved
liquidity in our shares and is another step towards our future goal
of listing on a national exchange.”

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the
treatment of cardiovascular disease and is a leader in devices that
stimulate cardiac angiogenesis. The company’s market leading
Holmium:YAG laser system and disposable fiber-optic accessories are
used to perform a FDA-cleared surgical procedure known as
Transmyocardial Revascularization (TMR) to treat patients suffering
from angina. Surgical products and accessories for the
Cardiogenesis TMR procedure, which are marketed in the U.S. and
around the world, have been shown to reduce angina and improve the
quality of life in patien

‘/>”/>

SOURCE